Novartis divvies up troubled Alcon; targets $1B in cuts in R&D and manufacturing rejig

Tracy Staton Novartis has a problem with its eye-care unit Alcon: It's not performing. As expected, the division dragged down the Swiss drugmaker's fourth-quarter and full-year ...

Takeda’s Millennium Pharmaceuticals R&D rejig unfolds

Ryan McBride Last month, Millennium CEO Deborah Dunsire stepped down and company veteran Anna Protopapas stepped in as president of the company, which will no longer operate as autonomously ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS